Automating assays in our drug discovery process has been key to keeping up with higher sample throughput and taking on a larger number of assays. We’ve created workflows that will spare reagents, save time, reduce human error, increase reproducibility and accuracy, and increase efficiencies. These workflows are focused on using lower volumes to save on resources such as enzymes, substrates, and other critical reagents as well as the use of specialized equipment. The Dragonfly has empowered us to support more projects and has been utilized as an assay robot as well as a key instrument for assay development.
dragonfly® discovery enables development of a 384-well arrayed CRISPR-Cas9 Gene Editing screen in T-cell Sana Desai, GSK
Functional genomics approaches to identify novel therapeutic targets are rapidly gaining traction. Arrayed screening for the phenotypes resulting from gene-knockouts using CRISPR-Cas9 technology can yield results rapidly, with very little need for target deconvolution. Data can be further enhanced by the selection of disease relevant primary cells. We have developed a high-efficiency, arrayed genome-editing screen in primary CD4+ T cells utilising the Dragonfly Discovery for sterile dispensing of T-cells and recombinant Cas9 protein. The development of miniaturised, robust nucleofection protocols and assays for arrayed CRISPR screening was enabled by this innovative, precise liquid handling platform that keep dead volumes for costly reagents such as recombinant Cas9 low, allowed for flexible dispensing of a range of liquid classes and maintained cell sterility for experiments with extended time courses.